Observational Study on the Impact of Herpes Zoster Vaccine on the Incidence of Herpes Zoster and Survival in Lung Cancer Patients

NCT07170059 | Not Yet Recruiting DMC

• 1 other identifier: ZSHV-LC-OBS2025
• Study Type: observational
• Target: 500
• Locations: 0 countries
• Sites: N/A

Brief Summary

To evaluate the impact of herpes zoster vaccine on the incidence of herpes zoster and survival in lung cancer patients, and to explore its preventive effect and safety.

Conditions

Lung Cancer

Outcome Measures

Primary Outcomes (2)

• The incidence of herpes zoster at 12 months

  During the 12-month follow-up period, the incidence of herpes zoster in lung cancer patients was evaluated through regular clinical examinations, imaging tests, and laboratory tests.

  12 months

• Incidence of herpes zoster

  The proportion of lung cancer patients who developed herpes zoster during the study period.

  24 months

Secondary Outcomes (1)

• Survival rate

  5 years

Other Outcomes (5)

• Lung cancer-related complications

  5 years

• Length of hospital stay

  5 years

• Hospitalization rate

  5 years

Study Arms (2)

Vaccination group

Lung cancer patients receive herpes zoster vaccine

Biological: herpes zoster vaccine

Unvaccinated group

Lung cancer patients have not received herpes zoster vaccine

Interventions

herpes zoster vaccine BIOLOGICAL

Receive the herpes zoster vaccine; Do not receive the herpes zoster vaccine

Vaccination group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Lung cancer patients can receive or not receive the herpes zoster vaccine

You may qualify if:

• Male or female patients \>=18 years of age; 2.Histological diagnosis of NSCLC, including both non-small cell lung cancer and small cell lung cancer, regardless of whether they are in the early, locally advanced stage or advanced stage, and regardless of whether they have received surgery, radiotherapy, chemotherapy or other treatments; 3. Never received herpes zoster vaccine

You may not qualify if:

• Patients having other factors that preventing researchers from enrollment them.

Sponsors & Collaborators

• The First Affiliated Hospital of Guangzhou Medical University: lead

MeSH Terms

Conditions

Lung Neoplasms

Interventions

Herpes Zoster Vaccine

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Chickenpox Vaccine; Herpesvirus Vaccines; Viral Vaccines; Vaccines; Biological Products; Complex Mixtures

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: The First Affiliated Hospital of Guangzhou Medical University

Study Record Dates

• First Submitted: September 7, 2025
• First Posted: September 12, 2025
• Study Start: October 1, 2025
• Primary Completion (Estimated): November 1, 2026
• Study Completion (Estimated): October 1, 2030
• Last Updated: September 12, 2025

Record last verified: 2025-09